LONDON, April 30 Drugmaker Shire said on
Wednesday that its Lifitegrast treatment for adults with dry eye
disease failed to meet one of two goals in a late-stage trial,
the same result it saw in trial results in December.
The drug met one goal for patient-reported symptoms of dry
eye compared with placebo, the company said, but did not meet
the second target based on signs of corneal staining.
Lifitegrast - a potential competitor for Allergan's
Restasis, which is expected to have sales of around $900 million
this year - is viewed as a key new product for Shire as it seeks
to diversify its product line-up.
(Reporting by Paul Sandle; Editing by Brenda Goh)